Indication: Cabozantinib is prescribed for treating various cancer types, including renal cell carcinoma (both advanced and hepatocellular carcinoma) and medullary thyroid cancer in patients with locally advanced or metastatic disease.

Pharmacology: Cabozantinib functions as a tyrosine kinase inhibitor, targeting multiple receptors involved in tumor growth and angiogenesis, such as MET, VEGFRs, and RET. Its action inhibits tumor growth, angiogenesis, and affects the tumor microenvironment.

Dosage and Administration: The recommended dosage of cabozantinib depends on the cancer type being treated. Typically, for renal cell carcinoma, the initial dose is 60 mg orally once daily, with potential adjustments based on individual patient factors and tolerability.

Interactions: Cabozantinib may interact with various medications, including strong CYP3A4 inhibitors and inducers. Patients should inform their healthcare providers about all medications to prevent potential interactions.

Side Effects: Common side effects of cabozantinib include fatigue, diarrhea, decreased appetite, nausea, hypertension, hand-foot syndrome, and weight loss. Serious side effects may include perforations, fistulas, hemorrhage, thromboembolism, hepatotoxicity, and osteonecrosis of the jaw.

Precautions and Warnings: Patients on cabozantinib should be monitored for signs of hypertension, proteinuria, hemorrhage, and perforations or fistulas. Regular liver function tests are advised, and patients should avoid activities that may increase bleeding risk.

Overdose Effects: In the event of overdose, supportive measures are recommended. No specific antidote exists for cabozantinib overdose, and treatment should focus on symptomatic and supportive care.